What is HC Wainwright’s Estimate for AGIO Q4 Earnings?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Stock analysts at HC Wainwright issued their Q4 2025 earnings estimates for Agios Pharmaceuticals in a research report issued on Monday, February 24th. HC Wainwright analyst E. Bodnar forecasts that the biopharmaceutical company will post earnings of ($1.42) per share for the quarter. HC Wainwright has a “Buy” rating and a $58.00 price target on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share.

Several other brokerages have also issued reports on AGIO. StockNews.com lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. Royal Bank of Canada lifted their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Finally, Scotiabank raised their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, December 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $56.57.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO opened at $35.47 on Tuesday. Agios Pharmaceuticals has a one year low of $27.14 and a one year high of $62.58. The business’s 50-day moving average price is $34.14 and its two-hundred day moving average price is $42.98. The company has a market capitalization of $2.03 billion, a P/E ratio of 3.13 and a beta of 0.88.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%.

Hedge Funds Weigh In On Agios Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Venturi Wealth Management LLC acquired a new stake in Agios Pharmaceuticals during the fourth quarter worth about $33,000. GF Fund Management CO. LTD. acquired a new position in Agios Pharmaceuticals in the 4th quarter valued at approximately $39,000. Wingate Wealth Advisors Inc. bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth approximately $53,000. Sterling Capital Management LLC grew its holdings in shares of Agios Pharmaceuticals by 818.0% during the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 1,587 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Agios Pharmaceuticals by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 363 shares during the period.

Insider Transactions at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the transaction, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.93% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.